Under the contract, RaQualia has licensed the development, manufacturing and commercialization rights of 5-HT4 Partial Agonist (RQ-00000010) to CJ in India, Taiwan, Korea and South Asia.
As per the terms of the agreement, CJ is responsible to pay an upfront payment to RaQualia.
Additionally, CJ will also pay development milestones and royalties on sales of products commercialized under the license to RaQualia.